Clinical Trial Update: A Study to Assess the Effects of Zigakibart on IgA Nephropathy. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial to assess the effects of Zigakibart on Immunoglobulin A Nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy

Drugs mentioned

• Zigakibart

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Status: RECRUITING